The decision was difficult but necessary, according to MaxQ CEO Michael Rosenberg. Algorithms designed to identify a specific clinical problem are only one part of a broader solution needed to have an impact on patient outcomes, he said.

Instead of developing AI algorithms that would be considered as medical devices and require regulatory approval, MaxQ is now building nonimage-based AI algorithms that will reach beyond the radiology department to the enterprise, Rosenberg said.

“Our new solution leverages the vast amount of medical data to identify anomalies that may cause poor…